Congress may eventually pass clear rules of the road regarding pre-approval and off-label communications for drugmakers, but current Republican proposals would likely need to include a series of extra safeguards, as well as more specificity with regard to the information sponsors can share to gain bipartisan support.
The subject was debated at a June 7 House Energy and Commerce Committee markup of the user fee reauthorization, which...







